New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2013
16:20 EDTVOD, ULTA, CTB, BIIB, LYV, HMA, GTOn The Fly: Closing Wrap
Stocks on Wall Street were lower despite opening sharply higher as the market looked to avoid its first three day losing streak of the year. Downside momentum quickly took hold however, and the averages moved steadily lower through the session, moving to their lows in the final hour of trading but finishing just off those levels. ECONOMIC EVENTS: In the U.S., the MBA's purchase applications composite index rose 5.0% for the week. The U.S. posted a $139B May budget deficit against expectations for a $130B deficit, and compared to a $124.6B deficit a year ago. In Europe, factory production in the 17-nation euro area rose 0.4% in April from March, compared to expectations for it to remain unchanged. COMPANY NEWS: Cooper Tire (CTB) agreed to be acquired by India's Apollo Tyres for $35.00 per share in cash, or $2.5B. Cooper shares surged $10.10, or 41.12%, to $34.66 to trade near $34.50 following the deal announcement, while peer Goodyear Tire (GT) advanced about 33c, or 2.26%, to $14.93... Live Nation (LYV) shares gained $2.33, or 16.84%, to $16.17 after the company announced it prevailed in an arbitration ruling related to a ticketing license software agreement... MAJOR MOVERS: Among the notable gainers was Ulta Salon (ULTA), up $12.51, or 14.87%, to $96.64 following its quarterly earnings report. Also higher was Health Management (HMA), up $1.58, or 11.34%, to $15.51 after Glenview Capital said in a filing it is seeking to repeal a provision that prevents entities from holding more than 15% of the company's stock and saying it would look to nominate candidates to the company's board. Among noteworthy losers was Biogen (BIIB), down $16.48, or 7.39%, to $206.55 after the stock was downgraded to Neutral from Buy at Citigroup, which cited concerns that EU medical regulators are unlikely to approve the company's multiple sclerosis treatment. Also lower were U.S.-listed shares of Vodafone (VOD), down 71c, or 2.47%, to $28.12 after the company confirmed it approached Kabel Deutschland about a possible deal. INDICES: The Dow was down 126.79, or 0.84%, to 14,995.23; the S&P 500 was down 13.61, or 0.84%, to 1,612.52; the Nasdaq was down 36.52, or 1.06%, to 3,400.43.
News For CTB;GT;LYV;ULTA;HMA;BIIB;VOD From The Last 14 Days
Check below for free stories on CTB;GT;LYV;ULTA;HMA;BIIB;VOD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
15:32 EDTBIIBNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Procter & Gamble (PG), consensus $1.02; Boeing (BA), consensus $1.56; Biogen Idec (BIIB), consensus $2.56; Dow Chemical (DOW), consensus 71c; EMC Corporation (EMC), consensus 35c; Thermo Fisher (TMO), consensus $1.40; Praxair (PX), consensus $1.51; General Dynamics (GD), consensus $1.64; Johnson Controls (JCI), consensus 65c; Norfolk Southern (NSC), consensus $1.15; Reynolds American (RAI), consensus 74c; Delta Air Lines (DAL), consensus 29c; Northrop Grumman (NOC), consensus $2.15; Air Products & Chemicals (APD), consensus $1.35; TD Ameritrade (AMTD), consensus 34c; Ingersoll-Rand (IR), consensus 26c; Dr Pepper Snapple (DPS), consensus 59c; Polaris Industries (PII), consensus $1.16; Ryder System (R), consensus 87c.
April 21, 2014
13:12 EDTVODEarnings Preview: AT&T sentiment mixed ahead of Q1 report
AT&T (T) is expected to report Q1 earnings after the market close on Tuesday, April 22, with a conference call scheduled for 4:30 pm ET. AT&T is a global telecommunications company offering wireless and long distance services. EXPECTATIONS: Analysts are looking for EPS of 70c on revenue of $32.41B, according to First Call. The consensus range for EPS is 64c-74c on revenue of $31.96B-$33.24B. LAST QUARTER: AT&T reported Q4 adjusted EPS of 53c against estimates for 50c, on revenue of $33.2B against estimates for $33.06B. Q4 postpaid churn was reported at 1.11%. AT&T reported the following in Q4: more than 500,000 branded smartphone net adds, including postpaid and prepaid; wireless operating income $1.4B; total postpaid ARPU up 2.1%; net increase in total wireless subscribers 809,000; connected device adds 398,000. On its Q4 earnings report, the company forecast FY14 adjusted EPS growth in the mid-single digits compared to a consensus at the time of $2.67. It expected FY14 revenue growth of 2%-3%, compared to the then consensus of $131.12B. On March 31, the board of AT&T authorized the repurchase of up to 300M shares, representing approximately 6% of AT&T common shares outstanding, with no expiration date. Due to the large share buyback program, The New York times noted that AT&T would be less likely to make a bid for Vodafone (VOD), something that had been speculated throughout the quarter. STREET RESEARCH: Street research has been mixed in the weeks leading up to AT&T's Q1 earnings report. On February 11, Drexel Hamilton initiated AT&T with a Buy rating and price target of $40. On March 25, HSBC downgraded AT&T to Neutral from Overweight based on expectations for increased industry price competition and a peak margin expansion. The firm lowered its price target on the shares to $35 from $39. PRICE ACTION: AT&Ts shares are up approximately 6% since the company's Q4 report, but are down about 6% from year ago levels. In early afternoon trading ahead of tomorrow's Q1 report, AT&Ts shares are trading near the flat line.
08:16 EDTBIIBBiogen signs Factor VIII license agreement with Amunix
Subscribe for More Information
07:42 EDTVODGreek partner seeks GBP1.1B from Vodafone over broken deal, Telegraph says
Subscribe for More Information
April 20, 2014
16:45 EDTBIIBBiogen hemophilia drug Alprolix priced similar to older treatments, Reuters says
Subscribe for More Information
April 19, 2014
21:07 EDTVODVodafone and France's SFR assessing network-sharing venture, WSJ says
Subscribe for More Information
April 17, 2014
20:00 EDTLYVLive Nation assumes sole ownership of Live Nation Japan
Live Nation Entertainment announced that it has acquired Creativeman's minority stake in Live Nation Japan, resulting in Live Nation Entertainment assuming full ownership.
12:46 EDTVODVodafone, Netflix in talks on content deal, Bloomberg says
Vodafone (VOD) is in early stage talks with Netflix (NFLX) to offer Vodafone customers free access access to its streaming service for a period of time, according to Bloomberg, citing three people familiar with the talks. Reference Link
06:37 EDTULTAUlta Salon volatility at low end of range
Subscribe for More Information
April 16, 2014
15:53 EDTULTAUlta Salon EPS may have been 'propped up' by accounting oddity, Greenberg says
Subscribe for More Information
08:34 EDTBIIBPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
08:29 EDTLYVLive Nation weakness creates buying opportunity, says Sterne Agee
Subscribe for More Information
April 14, 2014
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
April 11, 2014
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
06:53 EDTVODVodafone acquires stake in India unit for $1.5B, Bloomberg says
Vodafone will acquire Piramal Enterprises' stake in its India mobile-phone unit for $1.5B as the company ups its investments in the worlds quickest growing smartphone market, according to Bloomberg, citing a company statement from Piramal. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use